A little less than a year after targeting Moderna in an mRNA vaccine patent lawsuit, GSK is widening the scope of its litigation by throwing its rival’s next-generation COVID-19 shot into the fold. | ...

In the latest trading session, GSK (GSK) closed at $34.78, marking a -0.83% move from the previous day. This change was narrower than the S&P 500's daily loss of 1.2%. Elsewhere, the Dow lost 1.1%, ...

GSK plc (NYSE:GSK) is one of the best UK stocks to buy right now. On September 2, TD Cowen analyst Steve Scala maintained a Hold rating on GSK plc (NYSE:GSK) and set a price target of $45.00. The ...

In the latest trading session, GSK (GSK) closed at $35.30, marking a +0.89% move from the previous day. This change lagged the S&P 500's 1.49% gain on the day. Elsewhere, the Dow gained 1.6%, while ...

GSK announced today that Arexvy (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) will be offered through ...

GSK Canada (GlaxoSmithKline Inc.) today announced it has started shipping doses of its trivalent seasonal influenza vaccine, ...

OXFORD, England--(BUSINESS WIRE)--Ochre Bio, a pioneer in chronic liver disease medicine development, has today announced the start of a multi-year data licence agreement with GSK. The partnership ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. For the company’s closely watched respiratory syncytial virus (RSV) vaccine Arexvy, those ...

GSK is paying Adaptimmune 30 million pounds sterling ($37.3 million) to wipe its hands of two programs, one of which includes lete-cel, an asset the U.K. pharma at one point touted as its leading cell ...

GSK has stopped development of anti-TIGIT antibody belrestotug. The Big Pharma and its partner iTeos Therapeutics took the action after an assessment of the effect on progression-free survival fell ...

A £2m fund set up by a pharmaceutical giant after it decided to close a factory has awarded cash to a charity-run park and a community space offering help to residents. Last year, GlaxoSmithKline (GSK ...